EverPoint Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

EverPoint Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-64,000	Closed	-$6.68M	–	439
2015 Q1	$6.68M	Buy	64,000 +1,000	+2%	+$101K	0.13%	226
2014 Q4	$6.11M	Sell	63,000 -22,000	-26%	-$2.04M	0.14%	221
2014 Q3	$6.64M	Buy	85,000 +20,000	+31%	+$1.29M	0.15%	213
2014 Q2	$4.11M	Buy	+65,000	New	+$3.86M	0.08%	300

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

EverPoint Asset Management's ALNY Position: Q2 2015 in Review

EverPoint Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 64,000 shares — an estimated $6.68M sold.

EverPoint Asset Management first reported a position in ALNY in Q2 2014 and held it in 4 quarters. The position peaked at $6.68M in Q1 2015. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

EverPoint Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
EverPoint Asset Management sold 64,000 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $6.68M.
EverPoint Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 4 quarters.
EverPoint Asset Management's Alnylam Pharmaceuticals position peaked at $6.68M in Q1 2015.
278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on EverPoint Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.